



February 2026 CONFIDENTIAL

Dr Baloo:

“Imagine a world where cancer no longer means fear, suffering, or death. With **Nanobomb Plus**, we envision a future where tumors are shattered precisely at the source, without harming healthy tissues or debilitating side effects. An unmet clinical need. This is **Innovation through transformation** in how we fight cancer. The time is now. The technology is ready. The impact is global.”

An investment opportunity of a lifetime: Go-AI incorporating Nanotherapy Plus

Go-AI formally established in July 2024 is the cofounder of Nanotherapy Plus with Dr Balaji (Baloo) Panchapakesan. By agreement with Dr Baloo, Go-AI is the primary funder of Nanotherapy Plus. Go-AI is managed by a group of highly skilled professionals with complementary expertise and a single minded mission to provide change for a better world in cancer treatment. With that mission, Go-AI’s management is tasked to deliver substantial shareholder value. [Management Team \(go-ai.com.au\)](http://go-ai.com.au); [Technical Advisory Board \(go-ai.com.au\)](http://go-ai.com.au).

Its current equity interest is over 50% of Nanotherapy Plus which owns patent pending nano medical engineering technologies for the diagnosis and treatment of cancers: Liquid Biopsy Tracker for the diagnosis of cancers with a simple blood test, and Nanobomb Plus: the non-toxic non-invasive targeted and systemic treatment of cancers. Together, these technologies will support the “Test To Treat” strategy of the management.

The original Nanobomb was discovered in 2005 when an in-vitro study, funded by the US Department of Defence, successfully destroyed all breast cancer cells. The study was conducted by Dr Baloo at the US University of Delaware against breast cancer. Since 2005, Nanobomb has been much improved by Dr Baloo in close collaboration with Go-AI, in particular in the development of a targeted and systemic combination cancer therapy. These improvements are the subjects of provisional patent application by Nanotherapy Plus.

A total of 5.1 million limited offer of Go-AI shares have been earmarked for issue as private placement to professional and corporate investors under various tranches of the company’s Capital Management Plan: [Proposed Investment \(go-ai.com.au\)](http://go-ai.com.au)

First Tranche Offer of shares at A\$1 per share is completed and closed. Second Tranche Offer of A\$1 million of 500,000 shares at A\$2 per share through to pre IPO Offer are expected to raise a total of A\$27 million. The injection of the additional A\$27 million by Go-AI into Nanotherapy Plus will increase Go-AI’s equity interest in Nanotherapy Plus to over 60%. Completion of A\$27 million capital raise will allow Nanotherapy Plus to cover cost of patent application costs, preclinical mouse studies and phase 1+2 human clinical trials as well as prepare for phase 3 clinical trial. An allocation of A\$2 million is expected to be more than adequate to cover professional and regulatory costs of compliance listing in 2026 on an Australian stock exchange, on either the ASX or Cboe Australia Exchange, and cost of secondary listing on the Hong Kong Stock Exchange (HKSE), under Chapter 18A

(Biotech Sector) of its listing rules. Listing on HKSE is contemplated with expectation of much expanded liquidity and market valuation.

The A\$1 million Second Tranche Offer will finance the preclinical mouse studies at the Hong Kong Science and Technology Park Laboratory in the next 3 months. Completion of the preclinical study with positive results will qualify Nanobomb Plus to progress to human clinical trials at the Hong Kong University Clinical Trials Centre. Go-AI is confident of the success of the preclinical study since a preclinical in-vitro study in 2005 produced successful result destroying all breast cancer cells. Both HKSTPL and HKUCTC are accredited by the National Medical Products Administration (NMPA) (China's equivalent of FDA. The plan is to conduct phase 1 + 2 clinical trials at the HKUCTC so that upon results of successful trials, HKUCTC will connect with their network of hospitals in China to jointly conduct larger scale trials.

Second Tranche Offer raise of A\$1 million will be sufficient to cover the preclinical mouse studies with A\$200,000 budgeted for the preclinical study, and balance of funds to cover phase 1 + 2 clinical trials over the next 12 months. Successful completion of each stage of the preclinical study and phase 1 + 2 clinical trials will add tremendous incremental value to Nanotherapy Plus and therefore to Go-AI.

The data generated by the preclinical studies and clinical trials and owned by Nanotherapy Plus, will enable Go-AI/Nanotherapy Plus to approach major pharmaceutical companies such as Merck US for partnership or enter into distribution rights licensing deals. In the past two years, Merck US and Pfizer have invested multi-billion dollars to acquire distribution rights licenses or take over companies involved in novel cancer therapies. Merck US in particular is a valuable target partner for Go-AI to proactively engineer a combination therapy including Keytruda with Nanobomb Plus as Merck US is facing a patent cliff in 2028 of its Keytruda immunotherapy checkpoint inhibitor. Keytruda accounts for 40% or US\$30 billion of its annual revenue. Merck US has also been actively seeking distribution rights licenses and M&A opportunities in the China market from early stage pharmaceutical/biotech companies.

Any M&A approach to Go-AI can start with the global study of the Nanobomb Plus Platform. The global study of Nanobomb Plus Combination Therapy calculates a valuation of US\$198 billion for Nanotherapy Plus based on conservative assumptions including 196.9 cases per 100,000 people cancer incidence rate, being the global average (versus 614 cases per 100,000 people in Australia in 2025), and at 25% DCF discount rate, with the Hong Kong corporate tax rate reduced from 16.5% to 5% under the Hong Kong Patent Box Legislation for qualified entity such as Nanotherapy Plus. **60% of Nanotherapy Plus will deliver Go-AI a valuation of US\$118.8 billion equivalent to A\$1,508.57 per Go-AI share based on USD 75 cents to AUD \$1 on expected fully diluted 105 million Go-AI shares.**

It is about time the oncology world applies Nanobomb Plus Combination Therapy as first line treatment

The world is suffering from a silent pandemic of cancers. Cancer is a leading cause of death worldwide, accounting for over 10 million deaths in annually. The most common cancers are breast, lung, colon, rectum, and prostate cancers. (Source: WHO)

By comparison, cumulative global deaths from COVID from 2020 to 2024 total reportedly just over 7 million. Lung cancers are the no. 1 cause of cancer deaths at about double that of colorectal cancers the no. 2 cause of deaths. (Source: DeepSeek). **Australia has the highest cancer incidence rate in the**

world at about 614 cases per 100,000 people in 2025. Traditional cancer treatments including chemotherapy, radiation therapy, nuclear treatments, and surgery, will damage both healthy and cancer cells thus posing significant systemic risk. Quality of life of patients is impacted greatly during these traditional treatments. Moreover, these traditional treatments are costly without government subsidies, yet provide no assurance of a cure.

Instead, we believe the ground breaking Nanobomb Plus Combination Therapy should be the first line of treatment.

Nanobomb Plus can be given as a standalone treatment or in combination with immunotherapy drugs. Nanobomb Plus can also act as a delivery platform or carrier for targeted chemotherapy drug or special protein to activate the natural immunity pathways in combination therapy to further improve therapeutic and systemic efficacy in cancer treatment. The objective of Nanotherapy Plus is to improve treatment efficacy and survival outcome through early detection, followed by primary non-toxic Nanobomb Plus Combination Therapy, and with systemic immunotherapy to eliminate metastatic cancers, as well as to prevent tumour regrowth by providing ongoing prophylaxis supported by T-cell memory.

Hong Kong studies position Nanobomb Plus Combination Therapy for an efficient entry to the massive China oncology market

While most Australian biotech companies tend to look to the US market to make their mark, Go-AI/Nanotherapy Plus believe the China market will better position the group to launch its Combination Therapy globally and offers far more value to the group by enabling more efficient commercialization of Nanobomb Plus Combination Therapy. Conducting the preclinical study and clinical trials in Hong Kong via two renowned Hong Kong institutions fully accredited by the China equivalent of FDA will mean the study results will be acceptable to the China regulators. On the other hand, the recent announcement by Donald Trump of the imposition of 100% tariff on pharmaceutical products imported into the US market makes the US market much less attractive to many international pharmaceutical companies than the large China oncology market which is also a major supplier of Active Pharmaceutical Ingredients for drug manufacturing. The already announced significant retrenchment of staff at the US CDC and FDA by the US Department of Health and Human Services may well lead to more bureaucratic delay in drug and therapy approval in the US.

Considering the above, together with the lower cost of conducting preclinical and clinical studies in Hong Kong relative to that in Australia, Go-AI/Nanotherapy Plus believe their strategic decision to position the group's future development in Hong Kong for entry to the China market will save the group at least 3 to 5 years in lead time to commercialization of Nanobomb Plus Combination Therapy in the midst of the current global cancer pandemic that is expected to only get worse.

Cancer Council Victoria: "1 in 2 is too many"


"It's a stark reality that **1 in 2** of us will be diagnosed with cancer by the age of 85, so we'll all feel its impact one way or another. But this isn't a figure we should learn to accept, it's one we need to change.

Because 1 in 2 is too many.

Behind everyone's cancer diagnosis is a story that goes beyond a disease. It's the resilience, persistence, grit, and personal connections of the people facing cancer, the ones supporting them, and those behind the scenes working to save lives.

No story is the same, but everyone is impacted by the treatment, care, and support that's available to them."

Nanobomb Plus: Ushering in a New Era in Cancer Treatment



A precise strike on tumors. A spark for the immune system. A future where patients no longer fear the word cancer. Nanobomb Plus makes this future real — today.

DISCLAIMER

This document, including the Financial Model where provided, is provided for general information purposes only and does not take into account each person's individual circumstances. Accordingly, no person should rely or act on the contents of this document, without first obtaining advice from a qualified professional person. For the avoidance of doubt, this document, its author nor Go-AI Pty Ltd and its associates, its related bodies corporate and their respective officers and employees should not be regarded as providing investment advice. This document is supplied on the terms and understanding that:

1. Go-AI Pty Ltd, and their associates, their related bodies corporate and their respective officers and employees, are not responsible for the results of any actions taken or not taken on the basis of the information in this document;

2. Go-AI Pty Ltd does not warrant the accuracy, reliability or completeness of such information and (subject to any statutory liability which cannot be excluded) accepts no responsibility for any errors or omissions from this document (including by negligence).

3. To the maximum extent permitted by law, Go-AI Pty Ltd expressly disclaims all and any liability and responsibility to any person, in respect of anything, and for the consequences of anything, done or omitted to be done by any such person, whether wholly or partly, as a result of the contents (whether in whole or in part) of this document.